Skip to main content
main-content

Diabetes medications

medwireNews top story

Real-world data support early insulin pump initiation in children

Child with insulin pump

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Kidneys

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

medwireNews top story

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Male orderly pushing male patient discharged from hospital in wheelchair

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Remote landscape Victoria, Australia

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Heart and white pills

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

Featured podcast

EASD 2020: Editorial Board conference highlights

Sanjay Kalra, Lori Berard, John Wilding

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05). 

EASD 2020

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

Hiddo Heerspink

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Milton Packer

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

EASD 2020 News

Further VERTIS-CV analysis supports ertugliflozin renal benefits

Heart kidney and nerves

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

11-17-2020 | Heart failure | Commentary

Takeaways from the SCORED and SOLOIST-WHF trials

Deepak Bhatt discusses the performance of sotagliflozin in trials focusing on acute heart failure and on chronic kidney disease (11:56).

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity

Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.

10-14-2020 | Type 2 diabetes | Editorial | Article

Tirzepatide: A new challenger for type 2 diabetes management?

What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

Journal articles and book chapters

Learn about SGLT2 inhibitor use in type 2 diabetes management

Guidance from the Improving Diabetes Steering Committee

This content content collection includes details on:

  • A benefit/risk tool to inform prescribing decisions for SGLT2 inhibitors

  • The patient experience of diagnosis and self-management with SGLT2 inhibitors

  • Translating SGLT2 inhibitor cardiovascular evidence into practice
  • Key evidence and implications for clinical practice

This collection was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits